Skip to content
The GLP-1 Verdict
Menu
Ranked #30 · Grade B−

Direct Meds review

One of the rare programs offering an oral/sublingual route on both molecules with all-inclusive pricing — marked down hard because the numbers are company-stated rather than independently verified, and the company carries an FDA warning letter from September 2025.

Direct Meds — FDA warning letter, September 2025. Addressed to directmeds.com, Inc. dba DirectMeds, and public in FDA’s warning-letter database.

Visit Direct Meds Assume we may earn a commission, at no cost to you. It never changes The Verdict Score, nor a word of this review.
Semaglutide
$179/mo
Tirzepatide
$224/mo
Coverage
Not publicly listed
Brand-name
Compounded only

The scorecard

Direct Meds scored on our six published factors. See the methodology.

Real-world results80/100
Price honesty82/100
Prescriber access80/100
Formulary choice88/100
Cancellation fairness82/100
Member support80/100

What we like

  • Rare oral/sublingual drops on both molecules — sublingual semaglutide from $179/mo and tirzepatide from $224/mo — plus an injectable path
  • All-inclusive pricing with no separate membership fee to layer on top
  • Covers both semaglutide and tirzepatide rather than a single molecule

The caveats

  • Every option is compounded, not FDA-approved
  • Pricing is company-stated (from a press release) and not independently verified — treat the figures as claims, not confirmed rates
  • Newer entity (est. 2024) operating across several similar-looking domains, so confirm you're on the right one
  • States served are not disclosed, so coverage can't be verified before you sign up
  • FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025; it is public in FDA's warning-letter database

The verdict

Best for: Needle-averse patients who specifically want a sublingual GLP-1 option and are willing to vet a newer operator themselves. One of the rare programs offering an oral/sublingual route on both molecules with all-inclusive pricing — marked down hard because the numbers are company-stated rather than independently verified, and the company carries an FDA warning letter from September 2025.

Ranked #30 of 539 providers we have reviewed — for comparison, read our ruling on CoreAge Rx, our #1 pick. In the ranking it sits between Renlo Health at #29, 85/100 above and Alan Meds at #31, 84/100 below, with the Henry Meds ruling the next one down.

If that ruling leaves you undecided, the 7 programs we rank against Direct Meds are graded on the same six factors and listed in score order.If you would rather start from the top of the field, our full board of 539 providers is the place to start if you are still shortlisting. We have also ruled on it directly: CoreAge Rx vs Direct Meds goes to CoreAge Rx, 94/100 to 82/100.

Compare with other providers

The closest rulings to Direct Meds by Verdict Score — the realistic shortlist if you are weighing this one up.

Browse all 539 rulings, ranked →

Pricing, states and verification reflect Direct Meds's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Direct Meds's site. Not medical advice; see our disclosure.

← Back to all rankings